Bedrijfsoverzicht
STRATA Skin Sciences, Inc. is a medical technology company dedicated to the development, commercialization, and marketing of products designed for the treatment of various dermatologic conditions across a global footprint that includes the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates within the Healthcare sector, specifically in the Medical Devices industry, which positions it as a provider of specialized equipment and therapeutic solutions rather than pharmaceuticals. This entity employs a workforce of 114 individuals and maintains a market capitalization of $883,230, reflecting a relatively small market presence compared to large-cap healthcare peers. Its reported annual revenue over the trailing twelve months stands at $30.70M, indicating that while the company generates substantial top-line sales for its size, the low market cap suggests that the market values its future growth potential or asset base more heavily than current earnings generation.
Financiële gezondheid
Over the trailing twelve months, STRATA Skin Sciences reported revenue of $30.70M alongside a net income of $-6,261,000, a significant discrepancy that reveals a highly leveraged cost structure where operating expenses and interest costs far exceed gross profitability. The company's EBITDA for the same period was $-1,712,000, further highlighting the strain on operational efficiency before financing costs and taxes. Free cash flow stands at $-1,333,250, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund expansion without external capital injections. In terms of profitability metrics, the gross margin is 58.3%, suggesting that the core product lines retain a healthy portion of revenue after direct costs, yet this is insufficient to cover overhead. The operating margin is a mere 0.4%, signaling that administrative and sales expenses are consuming almost all operating profit, while the profit margin is -20.4%, confirming a loss-making position relative to total revenue. The balance sheet presents a conservative cash position of $7.91M against a debt load of $16.27M, resulting in a debt-to-equity ratio of 559.42, which implies a highly leveraged financial structure reliant on equity rather than debt financing. Liquidity is constrained by a current ratio of 0.58, indicating that current assets are insufficient to cover current liabilities without asset liquidation. Furthermore, the return on equity is -158.9% and the return on assets is -11.1%, metrics that reveal that management has been unable to generate positive returns on the capital deployed by shareholders or the company's total asset base.
Waarderingsbeoordeling
The valuation metrics for STRATA Skin Sciences show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at -0.12, a figure that implies the market expects earnings to remain negative or volatile in the near term. The price-to-book ratio is 0.30, indicating that the stock trades at a significant discount to its book value, suggesting the market assigns a low premium to the company's tangible assets. Alternative valuation measures such as the price-to-sales ratio of 0.03 and an EV/EBITDA of -5.40 suggest that the company is valued primarily on sales potential rather than profitability or earnings multiples. The stock has exhibited extreme price volatility, with a 52-week high of $3.86 and a 52-week low of $0.12, placing the current share price at a level significantly below the recent highs and near the recent lows. The beta value of 0.34 indicates that the stock's price volatility is substantially lower than the broader market, suggesting it may move less dramatically in response to general market fluctuations despite its financial distress.
Growth & Income
The revenue growth year-over-year is -3.0%, while earnings growth is N/A, illustrating that the company is currently contracting in terms of sales rather than expanding its market share. Since earnings are not growing due to the negative net income, the decline in revenue suggests a tightening of the top line that exacerbates the losses rather than driving a turnaround. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains all capital to potentially fund operations or debt reduction. The overall growth and income profile is characterized by negative revenue momentum, negative earnings generation, and an absence of dividend income, presenting a scenario where the company relies entirely on external financing to sustain its activities in a shrinking revenue environment.